Sanofi (NASDAQ:SNY) Shares Acquired by Trivant Custom Portfolio Group LLC

Trivant Custom Portfolio Group LLC grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 47.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,680 shares of the company's stock after purchasing an additional 5,693 shares during the period. Trivant Custom Portfolio Group LLC's holdings in Sanofi were worth $981,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Invesco Ltd. raised its holdings in Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock worth $581,619,000 after purchasing an additional 408,752 shares during the period. Bank of America Corp DE grew its holdings in Sanofi by 3.8% in the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after purchasing an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after buying an additional 5,091,304 shares in the last quarter. Boston Partners raised its stake in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after buying an additional 2,501,073 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of Sanofi by 10.8% during the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock worth $182,164,000 after buying an additional 369,530 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Price Performance

SNY traded down $0.60 on Thursday, hitting $47.62. 2,782,958 shares of the company's stock were exchanged, compared to its average volume of 2,377,740. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The stock has a market cap of $116.79 billion, a price-to-earnings ratio of 17.01, a P/E/G ratio of 0.97 and a beta of 0.50. The firm has a 50-day moving average price of $51.35 and a 200-day moving average price of $52.01. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period in the previous year, the business posted $1.78 earnings per share. Sanofi's quarterly revenue was down 11.0% on a year-over-year basis. As a group, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were issued a dividend of $2.0369 per share. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, May 9th. Sanofi's payout ratio is currently 56.79%.

Analyst Ratings Changes

SNY has been the topic of a number of research analyst reports. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Finally, BNP Paribas assumed coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.